RPTOR and neoplasm: Tumors with Raptor/mTORC1-deficient ECs harbored increased tumor-infiltrating lymphocytes (TILs) with enhanced cytotoxic T cell activation markers, increased CD103+ DCs, and elevated GM-CSF.